Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma

Research output: Contribution to journalArticle

Abstract

Medullary thyroid carcinoma (MTC), both in patients and in preclinical models, is resistant to chemotherapy. In this study, we show that the anti-neovascular agent combretastatin A-4 phosphate prodrug (CA4P) in combination with doxorubicin was effective in curtailing tumor growth in a preclinical model of human MTC. This combination of combretastatin and doxorubicin extended the doubling time of established MTC tumors in nude mice to 29 days, compared to 12 days in untreated controls. This suggests that a combination of combretastatin and a cytotoxic chemotherapeutic agent may be an effective treatment for MTC.

Original languageEnglish (US)
Pages (from-to)157-160
Number of pages4
JournalOncology Reports
Volume8
Issue number1
StatePublished - 2001

Fingerprint

Doxorubicin
Cytotoxins
Prodrugs
Therapeutics
Nude Mice
Neoplasms
Phosphates
Drug Therapy
fosbretabulin
Medullary Thyroid cancer
Growth
combretastatin

Keywords

  • Angiogenesis
  • Antivascular therapy
  • Cancer chemotherapy
  • Neuroendocrine cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{0c613881048d45909c54f15955c83c25,
title = "Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma",
abstract = "Medullary thyroid carcinoma (MTC), both in patients and in preclinical models, is resistant to chemotherapy. In this study, we show that the anti-neovascular agent combretastatin A-4 phosphate prodrug (CA4P) in combination with doxorubicin was effective in curtailing tumor growth in a preclinical model of human MTC. This combination of combretastatin and doxorubicin extended the doubling time of established MTC tumors in nude mice to 29 days, compared to 12 days in untreated controls. This suggests that a combination of combretastatin and a cytotoxic chemotherapeutic agent may be an effective treatment for MTC.",
keywords = "Angiogenesis, Antivascular therapy, Cancer chemotherapy, Neuroendocrine cancer",
author = "Nelkin, {Barry D} and Ball, {Douglas W}",
year = "2001",
language = "English (US)",
volume = "8",
pages = "157--160",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma

AU - Nelkin, Barry D

AU - Ball, Douglas W

PY - 2001

Y1 - 2001

N2 - Medullary thyroid carcinoma (MTC), both in patients and in preclinical models, is resistant to chemotherapy. In this study, we show that the anti-neovascular agent combretastatin A-4 phosphate prodrug (CA4P) in combination with doxorubicin was effective in curtailing tumor growth in a preclinical model of human MTC. This combination of combretastatin and doxorubicin extended the doubling time of established MTC tumors in nude mice to 29 days, compared to 12 days in untreated controls. This suggests that a combination of combretastatin and a cytotoxic chemotherapeutic agent may be an effective treatment for MTC.

AB - Medullary thyroid carcinoma (MTC), both in patients and in preclinical models, is resistant to chemotherapy. In this study, we show that the anti-neovascular agent combretastatin A-4 phosphate prodrug (CA4P) in combination with doxorubicin was effective in curtailing tumor growth in a preclinical model of human MTC. This combination of combretastatin and doxorubicin extended the doubling time of established MTC tumors in nude mice to 29 days, compared to 12 days in untreated controls. This suggests that a combination of combretastatin and a cytotoxic chemotherapeutic agent may be an effective treatment for MTC.

KW - Angiogenesis

KW - Antivascular therapy

KW - Cancer chemotherapy

KW - Neuroendocrine cancer

UR - http://www.scopus.com/inward/record.url?scp=0035233996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035233996&partnerID=8YFLogxK

M3 - Article

C2 - 11115589

AN - SCOPUS:0035233996

VL - 8

SP - 157

EP - 160

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 1

ER -